Excerpt: This mitochondrial cytotoxic peptide, D-(KLAKLAK)2, was also coupled to the heptapeptide SMSIARL [53], isolated from an in vivo phage display peptide library, and specific target for the prostate vasculature. When this peptide was coupled to D-(KLAKLAK)2, only prostate tissue was destroyed. In prostate-cancer-prone transgenic TRAMP (transgenic adenocarcinoma of the mouse prostate model, [54]) this chimeric peptide postponed cancer development, thereby suggesting a potential alternative to the surgical approach used to treat this disease [53].
In some ways it is good to know PYC is using bits of science that is already tried and tested. The article also contains a section on how CPPs can be coupled with a cell-targeting peptide - a bit like a homing device. (refer section 3)
Another thing that interests me is the reference to KAI-9803. Kai got bought out by Amgen for good money, albeit with emphasis on a different drug, but the CPP portfolio was of interest to Amgen. I'm not entirely sure what happened but I think Amgen shut down the CPP program later.
PYC Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)